

PATENT USSN: 09/960,315
Atty Dkt: 034047.0041 (RIID 99-12A)

AMENDMENT**IN THE CLAIMS:**

Please amend the claims as follows:

1-16. Canceled

17. (Currently amended) A method of inducing a mean ELISA antibody titer of about 1×10^2 mg/ml or more against ricin toxin in a subject comprising administering to the subject an amount of a chemically deglycosylated ricin A-chain lacking about 50% of the mannose and most fucose residues present on the wild-type ricin toxin A-chain and having the ricin B-chain removed.

18. (Previously presented) The method of claim 17, wherein the deglycosylated ricin-A chain is chemically deglycosylated by treating a ricin A-chain with a mixture of sodium metaperiodate and sodium cyanoborohydride at a pH 3.5 for 1 hour at 4 °C.

19-20. Canceled.

21. (Original) The method of claim 17, wherein the amount is an immunogenic amount.

22. (Previously presented) The method of claim 21, wherein the immunogenic amount is about 0.01 µg to about 100 µg per kg of the weight of the subject.

23. (Previously presented) The method of claim 17, wherein two doses of the deglycosylated ricin A-chain are administered to the subject.

24. (Original) The method of claim 17, further comprising administering an adjuvant to the subject.

25. (Currently amended) A method for providing neutralizing antibodies against ricin toxin or preventing ricin intoxication in a subject comprising administering at least two doses of an

PATENT USSN: 09/960,315

Atty Dkt: 034047.0041 (RIID 99-12A)

immunogenic amount of a chemically deglycosylated ricin A-chain lacking about 50% of the mannose and most fucose residues present on the wild-type ricin toxin A-chain and having the ricin B-chain removed to the subject.

26-39. Canceled

40. (Presently presented) The method of claim 17, wherein the amount of deglycosylated ricin A-chain is administered in the form of a vaccine, an immunogenic composition, or a pharmaceutical composition.

41-43. Canceled

44. (Previously presented) The method of claim 40, wherein two doses of the vaccine, the immunogenic composition or the pharmaceutical composition provides neutralizing antibodies in a subject.

45. (Previously presented) The method of claim 40, wherein two doses of the vaccine, the immunogenic composition or the pharmaceutical composition prevents ricin intoxication in a subject.

46. (Previously presented) The method of claim 40, wherein the vaccine, the immunogenic composition or the pharmaceutical composition further comprises an adjuvant.